| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
During Q2, Akcea Therapeutics's (NASDAQ:AKCA) reported sales totaled $22.38 million. Despite a 12.89% in earnings, the company posted a loss of $51.09 million. Akcea Therapeutics collected $16.07 million in revenue during Q1, but reported earnings showed a $45.26 million loss.
Changes in earnings and sales indicate shifts in Akcea Therapeutics’s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed in a business. Generally, a higher ROCE suggests successful growth in a company and is a sign of higher earnings per share for shareholders in the future. In Q2, Akcea Therapeutics posted an ROCE of -0.11%.
It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.
ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Akcea Therapeutics is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will lead to higher returns and earnings per share growth.
In Akcea Therapeutics's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.
Akcea Therapeutics reported Q2 earnings per share at $-0.49/share, which did not meet analyst predictions of $-0.35/share.
Posted In: AKCA
